Press

Nexeon MedSystems Announces Fourth Quarter and Full Year Results

[fa icon="calendar"] April 5, 2018 - by : Company News

Company News

DALLAS, April 05, 2018 (GLOBE NEWSWIRE) -- Nexeon MedSystems Inc (”Nexeon”) (OTCQB:NXNN) a neurostimulation medical device company, announced today financial results for the fourth quarter and full year ended December 31, 2017.

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

“Brain on Blockchain” technologies can open up a world of possibilities for the betterment of humanity

[fa icon="calendar"] February 9, 2018 - by : William Rosellini of Nexeon & Avery Spencer of HealthMine

Human brains have to manage an inconceivably massive amount of information. By current estimations, we are offloading, transferring, and storing information upward of 2.5 quintillion bytes a day. In this, humans require a trustable mechanism for recalling and telling their story. And such technology could enable the betterment of the human species.

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Taglich Brothers Initiating Nexeon Coverage with Speculative Buy rating & 12-mo price target of $3/share

[fa icon="calendar"] January 16, 2018 - by : 4-Traders.com

NEW YORK, Jan. 16, 2018 (GLOBE NEWSWIRE) -- Taglich Brothers, Inc. announces that it has initiated coverage of Nexeon Medsystems Inc. (OTC:NXNN).

Nexeon MedSystems Inc., headquartered in Dallas, Texas, is a medical device company developing a neurostimulator technology platform for the treatment of disorders through the electrical stimulation of neural tissues.  The company’s first application of its Nexeon Neurostimulation System will be for the treatment of chronic medical conditions such as Parkinson’s and associated diseases in Europe.  The company’s Belgian-based Medi-Line subsidiary provides global medical device outsource manufacturing solutions for existing customers and long term supply contracts with Fortune 50 companies.

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 2 Comments

Bioelectronics for Neuro Diseases: Interview with Nexeon CEO Rosellini

[fa icon="calendar"] December 22, 2017 - by : Conn Hastings of MedGadget

Conn Hastings of MedGadget

Nexeon Medsytems is a medical device company focused on providing innovative neurostimulation products for patients suffering from debilitating neurological diseases, including Parkinson’s and essential tremor. It was founded in 2005 with the goal of changing how innovative ideas in the medical device industry move from concept to reality, with a focus on creating solutions for clinicians in their pursuit of improving patient outcomes.

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 1 Comment

SeeThruEquity Issues Update on Nexeon MedSystems, Inc. (OTCQB: NXNN)

[fa icon="calendar"] December 21, 2017 - by : Ajay Tandon of SeeThruEquity

Ajay Tandon of SeeThruEquity

NEW YORK, NY / ACCESSWIRE / December 21, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Nexeon MedSystems, Inc. (OTCQB: NXNN).

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Nexeon MedSystems to Host Shareholder Update November 20th, 2017

[fa icon="calendar"] November 16, 2017 - by : Company News

Company News

Nexeon MedSystems (OTCQB: NXNN) announced today a conference call to discuss 2017 results.  The call is scheduled for 4:00 p.m.  Central Standard Time on November 20th, 2017.   Analysts, investors, and other interested parties may access via conference line (https://www.uberconference.com/nexeon) or dialing an optional dial in number: 469-551-9824.  The call will also be archived on the Company investor relations page.

Topics: Conference Call

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Nexeon Begins Clinical Study with Non-Invasive Vagus Nerve Stimulator

[fa icon="calendar"] October 25, 2017 - by : Company News

Company News

Feasibility Study for Treatment of Atrial Fibrillation is First Phase of €3.4M BioWin Award

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 1 Comment

Nexeon MedSystems Keeps Developments Flowing with New Clinical Study Treating Atrial Fibrillation

[fa icon="calendar"] October 25, 2017 - by : Baystreet Staff

Baystreet Staff

Normally an acquisition and commencing a clinical trial are productive events for a small company, especially those in the hot "medtech" sector, but that hasn't been the case for Nexeon MedSystems Inc. (OTCQB:NXNN). The Belgium-based bioelectronics medical device company with an emphasis on neurological diseases has seen shares slide since they began trading less than a month ago from $2.00 each to under $1.00.

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Nexeon Awarded Research Grant to Develop Neurostim Therapy for Asthma

[fa icon="calendar"] October 19, 2017 - by : Company News

Company News

Nexeon MedSystems Inc (OTC:QB “NXNN”) announced today that it has received a Phase I Small Business Research Innovation (SBIR) grant from the National Heart, Lung and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), to develop a neurostimulation therapy for asthma in collaboration with researchers at Oregon Health Sciences University. The funding award was granted due to the merits of the proposed development plan for a novel asthma treatment related to airway constriction. This therapy would be a second-line defense for patients whose current medications do not adequately treat their asthma.

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Nexeon MedSystems Begins Trading as NXNN

[fa icon="calendar"] September 28, 2017 - by : Company News

Company News

Dallas, TX -- Nexeon MedSystems, Inc. (OTC:QB NXNN) announced today that it has commenced "regular way" trading on the OTC Market (OTC:QB) under the symbol "NXNN".  The Company is finalizing development of its deep brain stimulation system for the treatment of symptoms associated with Parkinson's disease. 

Read More [fa icon="long-arrow-right"]

[fa icon="comment"] 0 Comments

Subscribe to Email Updates